NIH Adjuvant Therapy for Breast Cancer Panel to Address 7 Issues

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

BETHESDA, Md-Speakers at the National Institutes of Health Consensus Development Conference on Adjuvant Therapy for Breast Cancer will address the data on adjuvant chemotherapy, hormonal therapy, and other aspects of postsurgical treatment. The 2½-day meeting convenes on Nov. 1.

BETHESDA, Md—Speakers at the National Institutes of Health Consensus Development Conference on Adjuvant Therapy for Breast Cancer will address the data on adjuvant chemotherapy, hormonal therapy, and other aspects of postsurgical treatment. The 2½-day meeting convenes on Nov. 1.

Following a day and a half of presentations, an independent, nonfederal panel will weigh the evidence and prepare a conference statement making recommendations for clinical practice. The seven questions posed to the panel are:

• Which factors should be used to select systemic adjuvant therapy?

• For which patients should adjuvant hormonal therapy be recommended?

• For which patients should adjuvant chemotherapy be recommended?

• Which chemotherapy agents should be used and at what dose or schedule?

• For which patients should postmas-tectomy radiotherapy be recommended?

• How do side effects and quality-of-life issues factor into individual decision-making about adjuvant therapy?

• What are promising new research directions?

Patricia Eifel, MD, professor of radiation oncology, M.D. Anderson Cancer Center, will chair the panel. The conference’s major sponsors are the NIH Office of Medical Applications of Research and the National Cancer Institute.

Those interested in attending the conference can register on the website (http://odp.od.nih.gov/consensus) or by email (breastcancer@prospectassoc.com). Registration is free. The conference agenda can also be found at the website.

Additional information on the conference is available by calling 301-592-3320.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.